The consideration for Amyris Brasil Ltda (which owns and operates the Brotas 1 production facility) and intellectual property related to farnesene (a bio-based key intermediate for many applications) is $58 million plus an additional value share arrangement over a three-year period amounting to $37.5 million (aggregate upfront consideration of $96 million). In addition to the consideration upfront, there is potential for a future value share in line with Amyris’ business model, according to the companies.
DSM will continue existing supply-agreements to Amyris and other parties. DSM will also supply Amyris with specialty compounds until it realizes its Brotas 2 specialties production facility. Amyris is accelerating the construction of its second facility dedicated to specialty products while maintaining the manufacturing process development and business support capability located in Campinas, Brazil.
With the acquisition of the Brotas 1 facility, DSM adds a state-of-the-art biotechnology-based production site in Brazil to its global network, with abundant availability of sustainable raw materials (sugar cane), securing production capacity for its rich pipeline of sustainable and bio-based solutions. Having broad experience in operating large-scale fermentation plants, DSM will optimize the operational performance of the site.